Mimrylo (rusfertide)
Takeda Pharmaceuticals America (TAK)
ApprovedAug 28, 2026
Marketer take
A new way to control erythrocytosis in polycythemia vera, so hematologist messaging will center on where it fits relative to phlebotomy and existing cytoreductive drugs.
- Sponsor company
- Takeda Pharmaceuticals America (TAK)
- Indication
- To treat erythrocytosis in adults with polycythemia vera
- Therapeutic area
- Hematology
- Event
- FDA approval
- Date
- Aug 28, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?